{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:31:39Z","timestamp":1773297099655,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,10,19]],"date-time":"2011-10-19T00:00:00Z","timestamp":1318982400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s12032-011-0089-4","type":"journal-article","created":{"date-parts":[[2011,10,18]],"date-time":"2011-10-18T15:52:57Z","timestamp":1318953177000},"page":"2234-2239","source":"Crossref","is-referenced-by-count":17,"title":["Prostate-specific membrane antigen: a new potential prognostic marker of osteosarcoma"],"prefix":"10.1007","volume":"29","author":[{"given":"Chao","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zun-Fu","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Cong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can-Qiao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian-Tang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,19]]},"reference":[{"key":"89_CR1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.blo.0000145991.65770.e6","volume":"429","author":"HJ Mankin","year":"2004","unstructured":"Mankin HJ, Hornicek FJ, Rosenberg AE, et al. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res. 2004;429:286\u201391.","journal-title":"Clin Orthop Relat Res"},{"key":"89_CR2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000227564","volume":"53","author":"T Wada","year":"1996","unstructured":"Wada T, Isu K, Takeda N, et al. A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor. Oncology. 1996;53:221\u20137.","journal-title":"Oncology."},{"key":"89_CR3","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJM199511233332103","volume":"333","author":"N Baldini","year":"1995","unstructured":"Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of p-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med. 1995;333:1380\u20135.","journal-title":"N Engl J Med"},{"key":"89_CR4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<71::AID-CNCR13>3.0.CO;2-5","volume":"77","author":"M Onda","year":"1996","unstructured":"Onda M, Matsuda S, Higaki S, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer. 1996;77:71\u20138.","journal-title":"Cancer."},{"key":"89_CR5","first-page":"1807","volume":"54","author":"RS Israeli","year":"1994","unstructured":"Israeli RS, Powell CT, Corr JG, et al. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54:1807\u201311.","journal-title":"Cancer Res"},{"key":"89_CR6","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0022-3565(24)37683-9","volume":"286","author":"R Luthi-Carter","year":"1998","unstructured":"Luthi-Carter R, Barczak AK, Speno H, et al. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther. 1998;286:1020\u20135.","journal-title":"J Pharmacol Exp Ther"},{"key":"89_CR7","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1073\/pnas.1530168100","volume":"100","author":"GD Ghadge","year":"2003","unstructured":"Ghadge GD, Slusher BS, Bodner A, et al. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci USA. 2003;100:9554\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"89_CR8","first-page":"3629","volume":"57","author":"H Liu","year":"1997","unstructured":"Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57:3629\u201334.","journal-title":"Cancer Res"},{"key":"89_CR9","first-page":"3192","volume":"59","author":"SS Chang","year":"1999","unstructured":"Chang SS, Reuter VE, Heston WD, et al. Five different anti-PSMA antibodies confirm prostate-specific membrane antigen (PSMA) expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192\u20138.","journal-title":"Cancer Res"},{"key":"89_CR10","first-page":"4049","volume":"6","author":"JL Gala","year":"2000","unstructured":"Gala JL, Loric S, Guiot Y, et al. Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value? Clin Cancer Res. 2000;6:4049\u201354.","journal-title":"Clin Cancer Res"},{"key":"89_CR11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10895-007-0163-7","volume":"17","author":"X Yu","year":"2007","unstructured":"Yu X, Chen L, Deng Y, et al. Fluorescence analysis with quantum dot probes for hepatoma under one- and two-photon excitation. J Fluoresc. 2007;17:243\u20137.","journal-title":"J Fluoresc"},{"key":"89_CR12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10330-007-0188-z","volume":"7","author":"C Chen","year":"2008","unstructured":"Chen C, Chen LD, Zhang ZL, et al. Advances in the application of quantum dots in tumor markers investigation. Chin Ger J Clin Oncol. 2008;7:179\u201384.","journal-title":"Chin Ger J Clin Oncol."},{"key":"89_CR13","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1016\/j.biomaterials.2008.07.025","volume":"29","author":"LD Chen","year":"2008","unstructured":"Chen LD, Liu J, Yu XF, et al. The biocompatibility of quantum dot probes used for the targeted imaging carcinoma metastasis. Biomaterials. 2008;29:4170\u20136.","journal-title":"Biomaterials"},{"key":"89_CR14","first-page":"927","volume":"7","author":"JS Horoszewicz","year":"1987","unstructured":"Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927\u201336.","journal-title":"Anticancer Res"},{"key":"89_CR15","first-page":"6306","volume":"54","author":"RS Israeli","year":"1994","unstructured":"Israeli RS, Miller WH, Su SL, et al. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostatespecific antigen based assays. Cancer Res. 1994;54:6306\u201310.","journal-title":"Cancer Res"},{"key":"89_CR16","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/clinchem\/41.12.1698","volume":"41","author":"S Loric","year":"1995","unstructured":"Loric S, Dumas F, Eschwege P, et al. Enhanced detection of hematogenous circulating prostatic cells in patients with prostatic adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostatespecific membrane antigen. Clin Chem. 1995;41:1698\u2013704.","journal-title":"Clin Chem"},{"key":"89_CR17","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(05)61125-7","volume":"351","author":"BH Maraj","year":"1998","unstructured":"Maraj BH, Aldersley MA, Markham AF. Prostatespecific membrane antigen expression in the duodenum: implications in coeliac disease and immunotherapy for prostate cancer. Lancet. 1998;351:1559\u201360.","journal-title":"Lancet"},{"key":"89_CR18","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/(SICI)1097-0215(19990315)80:6<799::AID-IJC1>3.0.CO;2-U","volume":"80","author":"J Dumas","year":"1999","unstructured":"Dumas J, Gala JL, Berteau P, et al. Molecular expression of PSMA mRNA and protein in primary renal tumors. Int J Cancer. 1999;80:799\u2013803.","journal-title":"Int J Cancer"},{"key":"89_CR19","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.4049\/jimmunol.160.12.6188","volume":"160","author":"M Gueguen","year":"1998","unstructured":"Gueguen M, Patard JJ, Brasseur F, et al. An antigen recognized by autologous CTLs on a human bladder carcinoma. J Immunol. 1998;160:6188\u201394.","journal-title":"J Immunol"},{"key":"89_CR20","first-page":"2674","volume":"5","author":"SS Chang","year":"1999","unstructured":"Chang SS, O\u2019Keefe DS, Bacich DJ, et al. Prostate-specific membrane antigen is produced in tumorassociated neovasculature. Clin Cancer Res. 1999;5:2674\u201381.","journal-title":"Clin Cancer Res"},{"key":"89_CR21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","volume":"52","author":"SD Sweat","year":"1998","unstructured":"Sweat SD, Pacelli A, Murphy GP, et al. Prostate specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. J Urol. 1998;52:637\u201340.","journal-title":"J Urol"},{"key":"89_CR22","first-page":"6357","volume":"9","author":"JS Ross","year":"2003","unstructured":"Ross JS, Sheehan CE, Fisher HAG, et al. Correlation of primary tumorprostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357\u201362.","journal-title":"Clin Cancer Res"},{"key":"89_CR23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/1055-9965.EPI-07-0511","volume":"17","author":"MF Paulette","year":"2008","unstructured":"Paulette MF, Smiraglia DJ, Bshara W, et al. Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2008;17:571\u20137.","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-0089-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-011-0089-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-0089-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:51:00Z","timestamp":1741827060000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-011-0089-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,19]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["89"],"URL":"https:\/\/doi.org\/10.1007\/s12032-011-0089-4","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,19]]}}}